Form 4: Amgen Director Amy Miles Acquires Shares Through Equity Incentive Program

Amgen Inc. Director Amy E. Miles acquired 809 shares of common stock on May 23, 2025, through the company's Director Incentive Program, increasing her total beneficial ownership to 4,842 shares.

Summary

• Amy E. Miles, a Director of Amgen Inc. (AMGN), acquired 809 shares of common stock.
• The transaction occurred on May 23, 2025.
• The shares were acquired at a price of $0, indicating a grant rather than a cash purchase.
• These shares were granted as Restricted Stock Units (RSUs) pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, and vested immediately.
• Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis, with an option for deferral.
• Following this transaction, Ms. Miles beneficially owns a total of 4,842 shares of Amgen common stock.
• The total shares beneficially owned include 275 Dividend Equivalents (DEs) granted under the Director Program and subject to a qualifying dividend reinvestment plan, credited on vested but deferred RSUs and paid out in shares.

Sentiment

Score: 7

Explanation: The filing reports a routine grant of shares to a director as part of an incentive program, which is a positive sign of aligning management interests with shareholders and is a standard practice for public companies. It contains no negative or unexpected information.

Positives

• The acquisition of shares by a director, Amy E. Miles, aligns her interests with those of the company's shareholders.
• The grant of Restricted Stock Units (RSUs) and Dividend Equivalents (DEs) demonstrates the company's commitment to long-term equity-based incentive programs for its directors, fostering retention and performance alignment.

Negatives

• No negative aspects are directly indicated by this Form 4 filing, which primarily reports a routine insider transaction.

Risks

• This Form 4 filing is a routine insider transaction report and does not disclose specific risks to the company's operations or financial health.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information relevant to broader industry trends or competitive analysis within the biotechnology or pharmaceutical sector.

Corporate Governance

Related Party Transactions

• Acquisition of 809 shares of common stock by Director Amy E. Miles from Amgen Inc. as part of the company's 2009 Director Incentive Program, representing a compensation transaction between a related party (director) and the issuer.

Stakeholder Impact

• Shareholders: The transaction aligns the financial interests of Director Amy E. Miles with those of the shareholders through equity-based compensation, potentially fostering long-term value creation.
• Employees: This specific director transaction does not directly impact the broader employee base.

Key Dates

Recommendation

Keywords

Amgen, AMGN, Form 4, insider transaction, stock acquisition, director compensation, Restricted Stock Units, RSU, Dividend Equivalents, equity incentive plan